Guangzhou Institute of Respiratory Disease
Guangzhou Institute of Respiratory Disease
Explore linked clinical trials.16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC | non-small cell lung carcinoma | Not yet recruiting | Phase 2 | 2026-07-06 | NCT07685197 | |
| Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2026-06-08 | NCT06497530 | |
| Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2026-05-28 | NCT07610616 | |
| Nutritional + Usual Corticosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Utilization Evaluation | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Infections, lung disorder, neoplasm, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Not yet recruiting | Not applicable | 2026-05-26 | NCT07554885 | |
| Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-05-04 | NCT05491811 | |
| Personalized Prediction Strategy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Not stated | 2026-01-12 | NCT03240315 | |
| Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2025-07-29 | NCT07092137 | |
| Interventional Ablation for Early-stage Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not stated | 2025-06-05 | NCT07005999 | |
| Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Not yet recruiting | Phase 2 | 2025-04-03 | NCT06909383 | |
| The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Enrolling by invitation | Not stated | 2025-02-28 | NCT06851403 | |
| Association Between Genetic Polymorphisms and Type 2 Asthma in Children | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, disease susceptibility, hereditary disease | Recruiting | Not stated | 2025-02-21 | NCT06840717 | |
| To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Not stated | 2025-01-13 | NCT06772454 | |
| Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC | Small Cell Lung Cancer Extensive Stage | Recruiting | Phase 2 | 2024-12-18 | NCT06739928 | |
| Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis | Non-cystic Fibrosis Bronchiectasis (NCFBE) | Not yet recruiting | Not stated | 2024-12-04 | NCT06715956 | |
| Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis | Bacterial Infections and Mycoses, Hypersensitivity, Immediate, Infections, Respiratory Hypersensitivity, allergic bronchopulmonary aspergillosis, aspergillosis, fungal infectious disease, fungal lung infectious disease, immune system disorder, lung disorder, pulmonary aspergilloma, respiratory system disorder, respiratory tract infectious disorder | Not yet recruiting | Not stated | 2024-10-16 | NCT06645210 | |
| An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Not yet recruiting | Not stated | 2023-03-08 | NCT05759325 |